glp 1 pharmaceuticals GLP-1 Drugs from the Gray Market The GLP-1 Revolution: From Diabetes

95% CI 0.310.50), MACEs (aHR 0.66

This results in reduced caloric consumption and weight loss.

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), widely used for metabolic disorders, have emerged as promising candidates for a range of neuropsychiatric conditions due to their broad neurobiological effects

Common nutritional concerns associated with GLP-1 therapy may include: Reduced appetite and inadequate nutrient intake Loss of lean muscle mass during rapid weight reduction Nausea, digestive discomfort, and poor food tolerance Fatigue and reduced energy levels Micronutrient deficiencies over long-term use Increased nutritional needs in patients with complex clinical conditions Effective GLP-1 treatment requires more than medication alone

When branded therapies of semaglutide (Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound) commanded high prices and faced prolonged shortages from late 2022 through early 2025, compounding pharmacies emerged as alternative providers offering lower-cost formulations